Clinical trials: Thymic Carcinoid
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Thymoma, Thymic Carcinoma
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Background: Cisplatin-containing chemotherapy is the standard of care for advanced thymoma and thymic carcinoma that cannot be treated with surgery.
- Conditions
- Thymoma, Thymic Carcinoma, Thymic Carcinoid, Thymic Neuroendocrine Tumors
- Trial name
- NCT00965250
- Testing
- IMC-12
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoid Tumor
A Study of Axitinib in Advanced Carcinoid Tumors
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing.
- Trial name
- NCT01435122
- Testing
- Axitinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute